Idorsia Ltd
SIX:IDIA
Idorsia Ltd
SIX:IDIA
Price:
2.312 CHF
7.04%
Updated:
May 14, 2024
Idorsia Ltd
Operating Income
|
Idorsia Ltd
Operating Income Peer Comparison
Comparables:
ADCT
ACIU
CRSP
BSLN
KURN
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Idorsia Ltd
SIX:IDIA
|
Operating Income
-CHf803m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-152%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Operating Income
-$166m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Operating Income
-CHf53.6m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Operating Income
-$222.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Operating Income
CHf19.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Operating Income
-CHf8.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
See Also
What is Idorsia Ltd's Operating Income?
Operating Income
-803m
CHF
-803m
CHF
Based on the financial report for Dec 31, 2022, Idorsia Ltd's Operating Income amounts to -803m CHF.
What is Idorsia Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-152%
-152%
Over the last year, the Operating Income growth was -31%. The average annual Operating Income growth rates for Idorsia Ltd have been -19% over the past three years , -152% over the past five years .
You don't have any saved screeners yet
